We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$45.1M
1-Year Est. Return
74.25%
This Fund
S&P 500
This Quarter
Est. Return
+0.36%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$782M
AUM Growth
+$134M
(+21%)
Cap. Flow
-$119M
Cap. Flow
% of AUM
-15.2%
Top 10 Holdings %
Top 10 Hldgs %
66.62%
Holding
166
New
28
Increased
41
Reduced
46
Closed
40
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oramed Pharmaceuticals
ORMP
|
+$4.16M |
| 2 |
Nektar Therapeutics
NKTR
|
+$3.04M |
| 3 |
Viking Therapeutics
VKTX
|
+$1.95M |
| 4 |
FOLD
Amicus Therapeutics
FOLD
|
+$1.63M |
| 5 |
Genprex
GNPX
|
+$1.42M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$40.1M |
| 2 |
NVO
Novo Nordisk
NVO
|
+$19.8M |
| 3 |
SSKN
Strata Skin Sciences
SSKN
|
+$3.45M |
| 4 |
Incyte
INCY
|
+$2.77M |
| 5 |
AstraZeneca
AZN
|
+$2.59M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 15.01% |
| 2 | Consumer Staples | 0.29% |
| 3 | Financials | 0.12% |
| 4 | Technology | 0.09% |
| 5 | Materials | 0.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$777B
| $117M | 14.98% |
4,026
+1,626
| +68% | +$463K |
|
|
2
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$777B
| $116M | 14.88% |
4,001
+2,002
| +100% | +$570K |
|
3
PUT
iShares S&P 100 ETF
OEF
$19.7B
| $67.4M | 8.63% |
+4,000
| New | +$506K |
|
|
4
PUT
Biogen
BIIB
$31.8B
| $61.7M | 7.9% |
1,747
-704
| -29% | -$242K |
|
|
5
CALL
iShares S&P 100 ETF
OEF
$19.7B
| $35.6M | 4.56% |
2,115
-1,635
| -44% | -$207K |
|
|
ESPR
6
PUT
DELISTED
Esperion Therapeutics
ESPR
| $29.7M | 3.8% |
6,692
-296
| -4% | -$13.6K |
|
|
7
PUT
Nektar Therapeutics
NKTR
$2.32B
| $28.6M | 3.65% |
312
+114
| +58% | +$97.3K |
|
8
CALL
Sarepta Therapeutics
SRPT
$1.62B
| $28.2M | 3.61% |
1,746
-371
| -18% | -$50.7K |
|
9
CALL
State Street SPDR NYSE Technology ETF
XNTK
$1.97B
| $18M | 2.31% |
1,879
+450
| +31% | +$42.4K |
|
|
10
Nektar Therapeutics
NKTR
$2.32B
| $18M | 2.3% |
19,694
+3,566
| +22% | +$3.04M |
|
|
AMRN
11
CALL
Amarin Corp
AMRN
$298M
| $16M | 2.05% |
492
-43
| -8% | -$3.25K |
|
12
PUT
Tilray
TLRY
$479M
| $15.3M | 1.95% |
+106
| New | +$68.1K |
|
|
13
CALL
AstraZeneca
AZN
$271B
| $15.2M | 1.94% |
1,915
+549
| +40% | +$41.5K |
|
|
14
PUT
Sarepta Therapeutics
SRPT
$1.62B
| $14.7M | 1.88% |
908
| – | – |
|
|
15
PUT
AstraZeneca
AZN
$271B
| $14.3M | 1.83% |
1,803
+120
| +7% | +$9.08K |
|
|
ZGNX
16
CALL
DELISTED
Zogenix, Inc.
ZGNX
| $13.1M | 1.67% |
2,638
+915
| +53% | +$46.6K |
|
|
17
Biogen
BIIB
$31.8B
| $12.6M | 1.61% |
35,534
-116,568
| -77% | -$40.1M |
|
|
ZSAN
18
DELISTED
Zosano Pharma Corporation
ZSAN
| $12.4M | 1.59% |
7,165
-7,141
| -50% | -$1.05M |
|
|
ODT
19
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| $10.2M | 1.3% |
523,653
-54,946
| -9% | -$1.12M |
|
|
KYNB
20
PUT
Kyntra Bio
KYNB
$28.2M
| $8.77M | 1.12% |
58
+43
| +287% | +$66.2K |
|
21
Xeris Biopharma Holdings
XERS
$1.45B
| $8.56M | 1.1% |
486,938
+39,252
| +9% | +$852K |
|
|
22
PUT
Viking Therapeutics
VKTX
$3.87B
| $6.75M | 0.86% |
+3,873
| New | +$46.1K |
|
23
Cogent Biosciences
COGT
$6.8B
| $5.58M | 0.71% |
135,355
-9,971
| -7% | -$562K |
|
|
KYNB
24
CALL
Kyntra Bio
KYNB
$28.2M
| $5.57M | 0.71% |
+37
| New | +$57K |
|
|
SGMO
25
PUT
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $5.25M | 0.67% |
3,098
-442
| -12% | -$6.72K |
|
Similar funds
CG
OC
ICCON
PCM
CAS
CM
MCMC
CTC
Sabby Management's Q3 2018 Portfolio in Review
As of Q3 2018, Sabby Management held 166 positions worth $782M, up 21% from $647M the previous quarter. Its ten largest holdings account for 67% of the portfolio.
Sabby Management withdrew a net $119M in Q3 2018, closing 40 positions and reducing 46 holdings. Its most notable exit was Novo Nordisk, an estimated $19.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 15% of assets, down from 26% a quarter earlier, followed by Consumer Staples and Financials.
Against the trend, Sabby Management opened a new position in Oramed Pharmaceuticals worth $3.88M.
- Sabby Management's largest Q3 2018 buy was Oramed Pharmaceuticals: 801,242 shares worth $3.88M.
- Sabby Management added most to Nektar Therapeutics in Q3 2018, an estimated $3.04M increase.
- Sabby Management's biggest Q3 2018 reduction was Biogen, cutting an estimated $40.1M.
- Sabby Management fully exited Novo Nordisk in Q3 2018, selling an estimated $19.8M.
- Sabby Management's ten largest holdings make up 67% of its $782M portfolio in Q3 2018.
- Sabby Management opened 28 new positions and closed 40 in Q3 2018.
- Sabby Management's portfolio value rose 21% quarter-over-quarter to $782M.
Based on Sabby Management's 13F filing for Q3 2018, filed 14 Nov 2018.